Share on LinkedInShare on LinkedIn

ARTICLE · 31 OCTOBER 2018

Post-Priority Document Usable As Evidence Of POSITA Motivation

Jones Day
Jones Day
Contributor
Jones Day

Jones Day

Jones Day is a global law firm with more than 2,400 lawyers in 40 offices across five continents....

View firm profile
Explore more from Jones Day

The Federal Circuit recently affirmed the Patent Trial and Appeal Board's ("PTAB") final written decisions finding the claims of Yeda Research and Development Co., Ltd.'s.

United StatesIntellectual Property

The Federal Circuit recently affirmed the Patent Trial and Appeal Board's ("PTAB") final written decisions finding the claims of Yeda Research and Development Co., Ltd.'s ("Yeda") U.S. Patent Nos. 8,232,250, 8,399,413, and 8,969,302 unpatenable as obvious in three inter partes review proceedings by Petitioners, Mylan Pharmaceuticals Inc. and Amneal Pharmaceuticals LLC. Yeda Research and Development Co., Ltd. v. Mylan Pharmaceuticals Inc., Amneal Pharmaceuticals LLC, __ F. ___ (Fed. Cir. 2018).  The patents describe and claim the administration of a 40 mg dose of COPAXONE®, which is glatirmer acetate ("GA"), in three subcutaneous injections over seven days for the treatment for relapsing multiple sclerosis.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from